Login
Israel-Hamas Conflict
Benjamin Netanyahu
World Cup
Social Media
Military
Airstrike
Donald Trump
War
Cryptocurrency
Instagram
Soccer
MLB
Immigration
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

ViGeneron Rebrands as VeonGen Therapeutics, Announces Rare Pediatric Disease Designation for VG801

Summary by ophthalmologytimes.com
VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
modernretina.commodernretina.com

Rebranded VeonGen Therapeutics announces rare pediatric disease designation for VG801

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

Read Full Article
ophthalmologytimes.comophthalmologytimes.com

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

Read Full Article
Eyewire+Eyewire+

ViGeneron Rebrands as VeonGen Therapeutics; Announces FDA Rare Pediatric Disease Designation for Lead Gene Therapy

VeonGen Therapeutics announced its rebranding from ViGeneron to reflect its evolution into a clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high unmet medical needs. VeonGen has advanced two first-in-class gene therapy programs into clinical development. These programs include VG801, a novel dual AAV gene therapy for Stargardt disease and other ABCA4-related retinal disorders; and VG…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Eyewire+ broke the news in on Thursday, June 5, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
SearchBlindspotLocal